Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation

What Was Tested

The paper reports a study of Vasopressin, published as a clinical trial.

To determine the hemodynamic effect of vasopressin on coronary perfusion pressure (CPP) in prolonged human cardiac arrest.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, both men and women.

Ten patients presenting in cardiac arrest initially received resuscitative measures by emergency physicians according to Advanced Cardiac Life Support (ACLS) guidelines.

A central venous catheter for fluid and drug administration and a femoral artery catheter for measurement of CPP (aortic minus right atrial relaxation phase pressures) were placed.

How the Study Was Run

The researchers set it up as an open-label and pilot study.

Everyone knew when Vasopressin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It is described as a pilot, a small early test of whether a larger Vasopressin study would be practical.

A prospective, open-label clinical trial of vasopressin during cardiac resuscitation was performed.

CPP measurements were continued for another 5 minutes.

What Was Measured

PubMed files the paper under topics including Cardiopulmonary Resuscitation, Confidence Intervals, Coronary Circulation, Emergency Service, Hospital, Heart Arrest, Hemodynamics and Pilot Projects.

What This Means in Plain Language

The paper is an open-label and pilot study of Vasopressin.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1997 (Academic emergency medicine : official journal of the Society for Academic Emergency Medicine), a journal based in United States.

More context: the Vasopressin compound page, all human trials.